HER2/neu Antisense Therapeutics in Human Breast Cancer

doi 10.21236/ada470204
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/Neu

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Her2/Neu Protein Expression in Colorectal Cancer

Journal of Evolution of Medical and Dental Sciences
2019English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

Erratum To: NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Is Enhanced by Tamoxifen in HER2/neu Non-Amplified, but Not HER2/neu-amplified, Breast Cancer Cells

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2016English

Proteome and Transcriptome Profiles of a Her2/Neu-Driven Mouse Model of Breast Cancer

Proteomics - Clinical Applications
Clinical Biochemistry
2011English

An Antisense Transcript Mediates MALAT1 Response in Human Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Expression Levels of HER2/neu and Those of Collocated Genes at 17q12-21, in Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
2012English

ErbB-2/Her2/neu Overexpression and Estrogen-Dependency in Breast Carcinogenesis

2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy